Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Werutsky

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Hematology/Oncology and Stem Cell Therapy|April 5, 2011
AIDS-related sinonasal Burkitt lymphoma successfully treated with intensive chemotherapy regimen and high active antiretroviral therapyG Werutsky, G P de Carvalho, V D da Silva, et al.
Current Cancer Drug Targets|November 19, 2015
Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical CancerA Nogueira-Rodrigues, A C Melo, G Werutsky, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 1, 2016
The European Organization for Research and Treatment for Cancer (EORTC) strategy for quality assurance in surgical clinical research: Assessment of the past and moving towards the futureE Tanis, C Caballero, L Collette, et al.
Public Health|June 4, 2017
Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American regionJ Martínez-Mesa, G Werutsky, S Michiels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2014
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trialH Bonnefoi, S Litière, M Piccart, et al.
ESMO Open|May 8, 2024
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and driversL Vidal, Z Dlamini, S Qian, et al.
Breast Cancer Research : BCR|January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])A DeMichele, A C Dueck, D Hlauschek, et al.
ESMO Open|June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)M J Naughton, D M Zahrieh, M Gnant, et al.
ESMO Open|October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Hematology/Oncology and Stem Cell Therapy|April 5, 2011
AIDS-related sinonasal Burkitt lymphoma successfully treated with intensive chemotherapy regimen and high active antiretroviral therapyG Werutsky, G P de Carvalho, V D da Silva, et al.
Current Cancer Drug Targets|November 19, 2015
Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical CancerA Nogueira-Rodrigues, A C Melo, G Werutsky, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 1, 2016
The European Organization for Research and Treatment for Cancer (EORTC) strategy for quality assurance in surgical clinical research: Assessment of the past and moving towards the futureE Tanis, C Caballero, L Collette, et al.
Public Health|June 4, 2017
Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American regionJ Martínez-Mesa, G Werutsky, S Michiels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2014
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trialH Bonnefoi, S Litière, M Piccart, et al.
ESMO Open|May 8, 2024
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and driversL Vidal, Z Dlamini, S Qian, et al.
Breast Cancer Research : BCR|January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])A DeMichele, A C Dueck, D Hlauschek, et al.
ESMO Open|June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)M J Naughton, D M Zahrieh, M Gnant, et al.
ESMO Open|October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Pageof 1